Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ALPMYNASDAQ:GMABOTCMKTS:GNMSFNASDAQ:HZNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPMYAstellas Pharma$9.44-1.5%$9.63$8.37▼$13.14$17.08B0.27215,947 shs512,270 shsGMABGenmab A/S$19.93+2.9%$19.99$17.24▼$30.41$12.78B1.041.09 million shs2.60 million shsGNMSFGenmab A/S$197.45+2.2%$198.49$170.00▼$305.09$13.05B1.023,030 shs14,803 shsHZNPHorizon Therapeutics Public$116.30$115.72$60.03▼$116.38$26.63B1.032.50 million shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPMYAstellas Pharma-1.46%-7.00%+6.79%-0.94%-2.88%GMABGenmab A/S+2.78%-7.52%+5.95%+5.51%-30.89%GNMSFGenmab A/S+2.24%-10.46%+8.16%+5.72%-32.03%HZNPHorizon Therapeutics Public0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPMYAstellas PharmaN/AN/AN/AN/AN/AN/AN/AN/AGMABGenmab A/S4.4763 of 5 stars4.35.00.00.03.40.03.1GNMSFGenmab A/S0.5881 of 5 stars0.02.00.00.02.90.01.3HZNPHorizon Therapeutics Public0.8942 of 5 stars0.00.00.03.20.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPMYAstellas Pharma 0.00N/AN/AN/AGMABGenmab A/S 2.69Moderate Buy$39.1796.52% UpsideGNMSFGenmab A/S 0.00N/AN/AN/AHZNPHorizon Therapeutics Public 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALPMY, HZNP, GMAB, and GNMSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $37.004/1/2025GMABGenmab A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform3/11/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.003/11/2025GMABGenmab A/SWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform2/13/2025GMABGenmab A/SLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy2/13/2025GMABGenmab A/SLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$27.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPMYAstellas Pharma$11.11B1.54$1.12 per share8.42$5.84 per share1.62GMABGenmab A/S$21.64B0.59$1.35 per share14.80$8.04 per share2.48GNMSFGenmab A/S$3.12B4.18$13.44 per share14.69$80.53 per share2.45HZNPHorizon Therapeutics Public$3.63B7.34$7.05 per share16.49$22.38 per share5.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPMYAstellas Pharma$113M$0.17N/A13.88N/A-3.10%13.69%6.06%N/AGMABGenmab A/S$1.14B$1.7611.4511.202.6536.30%16.78%13.79%N/AGNMSFGenmab A/S$1.14B$17.6311.27∞N/A36.30%19.75%16.23%N/AHZNPHorizon Therapeutics Public$521.48M$1.8762.1920.553.9612.02%20.46%11.52%N/ALatest ALPMY, HZNP, GMAB, and GNMSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/8/2025Q1 2025GNMSFGenmab A/S$1.88$3.05+$1.17$3.05$761.09 million$765.14 million4/25/2025Q4 2025ALPMYAstellas Pharma$0.1474$0.27+$0.1226$0.27$3.02 billion$3.22 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPMYAstellas Pharma$0.333.50%N/A194.12%N/AGMABGenmab A/SN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/AHZNPHorizon Therapeutics PublicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPMYAstellas Pharma0.391.040.80GMABGenmab A/SN/A5.255.24GNMSFGenmab A/SN/A5.255.24HZNPHorizon Therapeutics Public0.484.274.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPMYAstellas PharmaN/AGMABGenmab A/S7.07%GNMSFGenmab A/SN/AHZNPHorizon Therapeutics Public80.37%Insider OwnershipCompanyInsider OwnershipALPMYAstellas PharmaN/AGMABGenmab A/S1.54%GNMSFGenmab A/S1.54%HZNPHorizon Therapeutics Public2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALPMYAstellas Pharma14,7541.81 billionN/ANot OptionableGMABGenmab A/S1,660641.20 million651.58 millionOptionableGNMSFGenmab A/S1,66066.08 million65.06 millionNot OptionableHZNPHorizon Therapeutics Public2,115228.99 million223.96 millionOptionableALPMY, HZNP, GMAB, and GNMSF HeadlinesRecent News About These CompaniesMaze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney DiseaseFebruary 8, 2025 | markets.businessinsider.comHorizon Therapeutics Public Lim (HZNP)April 27, 2024 | finance.yahoo.comPAC Profile: Horizon TherapeuticsDecember 25, 2023 | opensecrets.org5 Biotech Acquisition Targets To Accumulate In 2024December 21, 2023 | seekingalpha.comNasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business CombinationNovember 16, 2023 | msn.comHorizon Therapeutics cut jobs in Deerfield after Amgen acquisitionOctober 24, 2023 | chicago.suntimes.com350 Horizon Therapeutics workers to be laid off, mostly from Deerfield offices, following acquisition by AmgenOctober 24, 2023 | msn.comRule 17(e) Announcement - Horizon Therapeutics plcOctober 6, 2023 | finance.yahoo.com3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in OctoberOctober 5, 2023 | stocknews.comRule 17(d) Announcement - Horizon Therapeutics plcOctober 5, 2023 | stockhouse.comRule 17(d) Announcement – Horizon Therapeutics plcOctober 5, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023October 2, 2023 | finance.yahoo.comHorizon Therapeutics Plc (HZNP) Becoming More Attractive for InvestorsSeptember 27, 2023 | knoxdaily.comBoard Member at Horizon Therapeutics Exercises Options Worth $2.31MSeptember 26, 2023 | benzinga.comHorizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care IndustrySeptember 26, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 ListSeptember 19, 2023 | finance.yahoo.comHealth care: FTC Chair Lina Khan to crack down on 'below radar' dealsSeptember 19, 2023 | finance.yahoo.comQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia AreataSeptember 13, 2023 | finance.yahoo.comHZNP short interest jump by 15.39%, reflecting negative sentimentSeptember 7, 2023 | knoxdaily.comHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of ArrangementSeptember 5, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALPMY, HZNP, GMAB, and GNMSF Company DescriptionsAstellas Pharma OTCMKTS:ALPMY$9.44 -0.14 (-1.46%) As of 05/12/2025 03:59 PM EasternAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Genmab A/S NASDAQ:GMAB$19.93 +0.57 (+2.94%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$19.70 -0.23 (-1.16%) As of 07:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Genmab A/S OTCMKTS:GNMSF$197.45 +4.32 (+2.24%) As of 05/12/2025 10:24 AM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Horizon Therapeutics Public NASDAQ:HZNPHorizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
